POPULARITY
11 episodes with Drug resistance
7 episodes with Drug resistance
2 episodes with Drug resistance
3 episodes with Drug resistance
2 episodes with Drug resistance
4 episodes with Drug resistance
2 episodes with Drug resistance
2 episodes with Drug resistance
3 episodes with Drug resistance
In this conversation, Ryan Maves and Dennis discuss various aspects of tuberculosis, including recent outbreaks, public health implications, and treatment protocols. They delve into the complexities of managing tuberculosis in different contexts, particularly within military settings, and highlight the importance of public health initiatives like PEPFAR. The discussion also touches on the challenges posed by drug-resistant tuberculosis and the evolving landscape of health policy. In this conversation, Ryan Maves discusses the complexities of tuberculosis (TB), including its historical significance, transmission methods, diagnosis, treatment protocols, and the challenges posed by drug resistance. He emphasizes the importance of public health measures in managing TB outbreaks and reassures that most individuals with TB can recover with appropriate treatment. The discussion also highlights the role of good ventilation in reducing transmission risk and the need for awareness and screening in military and public health settings.TakeawaysTuberculosis outbreaks can be slow and complex, not immediate crises.Public health interventions are crucial for effective tuberculosis management.PEPFAR has saved millions of lives and is a significant achievement in global health.Drug-resistant tuberculosis presents unique challenges in treatment.Telemedicine can enhance the management of tuberculosis in remote settings.Understanding the transmission dynamics of tuberculosis is essential for prevention.Good ventilation and treatment protocols can mitigate tuberculosis risks.Public health policies can significantly impact disease control efforts.Collaboration and open dialogue are necessary for effective health policy.The importance of recognizing the long-term nature of tuberculosis management. Tuberculosis is a significant global health issue that has been impacted by the COVID-19 pandemic.HIV and tuberculosis have a close interaction, affecting incidence and outcomes.Active screening for tuberculosis is crucial, especially in military settings.Good ventilation and sunlight can significantly reduce the risk of TB transmission.Latent TB infection can progress to active disease if not treated promptly.The classic treatment regimen for active TB involves a combination of four drugs.Multi-drug resistant TB (MDR-TB) is a growing concern, particularly in certain regions.Rifampin is a key drug in TB treatment but has notable drug interactions.Most people with TB can recover with effective therapy, and treatment is often satisfying for healthcare providers.Public health measures are essential in managing TB outbreaks and ensuring community safety.Chapters00:00 Introduction and Personal Updates03:11 Understanding Tuberculosis Outbreaks06:00 Public Health and Policy Implications08:54 PEPFAR and Global Health Initiatives12:00 Tuberculosis in Military Contexts14:58 Diagnosis and Treatment of Tuberculosis18:01 Drug-Resistant Tuberculosis23:15 Understanding Tuberculosis: A Global Perspective27:43 Transmission and Infection: How TB Spreads33:31 Diagnosis and Screening: Identifying TB Cases41:41 Treatment Protocols: Managing Active and Latent TB51:29 Challenges of Drug Resistance in TB58:03 Public Health Response: Reporting and Managing OutbreaksThank you to Delta Development Team for in part, sponsoring this podcast.deltadevteam.comFor more content go to www.prolongedfieldcare.orgConsider supporting us: patreon.com/ProlongedFieldCareCollective or www.lobocoffeeco.com/product-page/prolonged-field-care
BUFFALO, NY - February 6, 2025 – A new #casereport was #published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report." In this case report, Jenny L. Wu from Vanderbilt University School of Medicine and Wade T. Iams from Vanderbilt-Ingram Cancer Center describe a rare case of drug resistance in a patient with advanced non-small cell lung cancer (NSCLC). The patient, a 42-year-old man who had never smoked, initially responded well to lorlatinib, a targeted therapy designed to treat cancer driven by specific genetic alterations. However, after six months, his cancer began to grow again. Clinicians discovered that this was due to a new genetic change, known as the RUFY1-RET fusion. This finding highlights how cancers can adapt to treatment and the importance of ongoing genetic testing to guide therapy decisions. NSCLC is the most common type of lung cancer, and in some cases, it is driven by genetic changes that can be targeted with specific drugs. The patient's cancer originally had a ROS1 gene rearrangement, which made it responsive to lorlatinib. But as time went on, the cancer started to grow again, and tests revealed a new genetic alteration called RUFY1-RET fusion, which likely caused resistance to lorlatinib. This new genetic change was identified using RNA next-generation sequencing (RNA NGS), an advanced test that can find mutations that standard genetic tests might miss. After discovering the RUFY1-RET gene fusion, the patient was treated with a combination of lorlatinib and pralsetinib, a drug that specifically targets RET gene alterations. While this combination helped control the cancer for about four months, the patient's condition unfortunately worsened after four months. “This is the first reported case of a RET fusion as a potential mechanism of resistance to lorlatinib, it identifies a novel RET fusion partner, and it emphasizes the importance of testing for acquired resistance mutations with both DNA and RNA at the time of progression in patients with targetable oncogenic drivers.” Understanding cases like this can help clinicians and researchers develop more effective treatment strategies, including combination therapies that target multiple genetic changes to combat drug resistance. While the combined therapy in this case provided only temporary benefits, it offers important insights for future research and patient care, particularly for cancers that no longer respond to standard treatments. DOI: https://doi.org/10.18632/oncotarget.28682 Correspondence to: Wade T. Iams, wade.t.iams@vumc.org Keywords: cancer, ROS1 rearrangement, RET rearrangement, non-small cell lung cancer, targeted therapy, case report Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
In this episode of Microbe Talk Clare spoke to Adam Aspinall who's Senior Director in the Access and Product Management team at Medicines for Malaria Venture. They discuss Malaria, antimalarial drug resistance and the work that Medicines for Malaria Venture is doing to support new drug discovery.If you'd like to find out more about the Microbiology Society's Knocking Out AMR project, you can do so here.If you'd like to find out more about the work that Medicines for Malaria do, take a look at their resources here: MMV website: http://mmv.orgSevere Malaria Observatory : severemalaria.orgMusic: Blue Dot Sessions - Blue Latex
We focus on drug resistance and the troubling news that the frontline drug against malaria, artemisinin, is failing due to resistant parasites in severe cases of malaria, and how the collective efforts of drug development – and the data produced – could be used to build an AI chatbot capable of predicting resistance before it strikes. With Robert Opoka and Elizabeth Winzeler. About The Podcast The Johns Hopkins Malaria Minute is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.
Researchers search for ways to predict antimalarial drug resistance and identify more effective drug combinations. Transcript The front-line treatment for malaria is typically a combination of drugs called artemisinin-based combination therapy. Resistance to treatment has already been reported in mild cases of malaria, but now, for the first time, it's also being reported in severe cases of malaria. Severe malaria cases are more likely to end in a fatal outcome, so drug resistance in these scenarios poses a risk to human life. To try and stay one step ahead of resistance, researchers tested compounds and combed through publications to identify 118 compounds active against over 700 parasite clones to see how the parasites evolve under pressure, and to identify mutations in the parasite genome likely to be associated with drug resistance. They confirmed that Plasmodium falciparum – the deadliest and most prevalent species of the malaria parasite – evolves relatively easily, with mutations that affect the drug's mechanism of action and which move through the population. The hope is that this dataset of drug resistance markers could provide an ‘early warning system' – to predict drug resistance in the field and to identify a more effective drug combination. Source Artemisinin Partial Resistance in Ugandan Children With Complicated Malaria (JAMA) Systematic in vitro evolution in Plasmodium falciparum reveals key determinants of drug resistance (Science) About The Podcast The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.
In this episode, Ayesha spoke with John Yu, MD, CEO of Kairos Pharma, a company advancing therapies to overcome challenges in cancer drug resistance and immune suppression. Kairos is developing therapeutics that reverse cancer drug resistance in cancers such as prostate and lung cancer. The company's lead candidate, ENV105, is an antibody targeting CD105, which is implicated in cancer cell resistance to various treatments. By inhibiting CD105, ENV105 seeks to restore the effectiveness of standard therapies across multiple cancer types. Dr. Yu is also Professor and Clinical Chief of Neurosurgery, Director of the Brain Tumor Center at Cedars Sinai Medical Center. He has developed numerous immunotherapies and nanotechnologies from his National Institutes of Health (NIH) funded laboratory. This includes eight new investigational drugs with the US Food and Drug Administration. Dr. Yu has also led numerous clinical trials. Dr. Yu served in leadership roles at several biotechs, including ImmunoCellular Therapeutics and most recently served as CEO and Chairman of AcTcell and Director of Enviro Therapeutics. Dr. Yu has an MD from Harvard Medical School and MIT, and completed an Immunology Fellowship at the Institut Pasteur, Paris. Tune into the episode, to hear more about the work Dr. Yu is leading at Kairos Pharma to address cancer drug resistance. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
How has drug resistance been addressed in the field of oncology? In this episode, Adam Torres and John Yu, CEO & Chairman at Kairos Pharma, Ltd., explore drug resistance and Kairos Pharma, Ltd. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia
How has drug resistance been addressed in the field of oncology? In this episode, Adam Torres and John Yu, CEO & Chairman at Kairos Pharma, Ltd., explore drug resistance and Kairos Pharma, Ltd. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit megaphone.fm/adchoices
Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.
First, Indian Express' Diplomatic Affairs Editor Shubhajit Roy discusses the recent coordinated attacks in Lebanon, where thousands of pagers and hand-held radios exploded, resulting in at least 37 deaths and over 3,500 injuries. He explains the implications for the region and the concerns it raises for New Delhi.Next, Indian Express' Anonna Dutt highlights the rising threat of antimicrobial resistance and addresses common misconceptions about antibiotics (10:36).Finally, we hear from Indian Express' Nihal Koshie talks about Olympic wrestler Vinesh Phogat's transition into politics (21:25).Further listening: Vinesh Phogat transitions from mat to political stageHosted and written by Shashank BhargavaProduced by Shashank Bhargava and Ichha Sharma
In Part 2 of our series on Hansen's Disease, Brig (Dr) J Muthukrishnan continues the discussion with Lt Col (Dr) Lekshmi Priya, Associate Professor in the Department of Dermatology at AFMC, Pune. This episode focuses on the key investigations for diagnosing leprosy, the use of multidrug therapy (MDT), and the management of complications. Dr. Lekshmi also discusses strategies to tackle drug resistance and the long-term care of patients.
Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk about the latest health news. Dr. Marty discusses the development of an antibiotic that would make it difficult to develop a drug resistance and when we could see it at the doctor’s office.
The problem of antimicrobial resistance – AMR for short – is clear. More and more of these germs resistant to existing treatments are emerging everywhere, and there's little disagreement that governments, nonprofits, doctors, patients, and politicians all need to help tackle the problem.But people need to agree on what to do, and they need to agree on how to measure progress.That's where targets come in.Aislinn Cook, a senior research fellow in infectious disease epidemiology on the antimicrobial resistance team in the Centre for Neonatal and Pediatric Infection of St. George's University in London, is helping set some of those targets. Cook, who's also affiliated with the Health Economics Research Centre at the University of Oxford, has helped write a series of papers in the Lancet medical journal bringing attention to the problem of antimicrobial resistance. AMR is a big topic of international discussion in 2024, due in part to it being one of the topics of the United Nations High-Level Meeting, and the Lancet series was put together to help focus that discussion.Cook's paper proposes some clear targets to reach by 2030: a 10 percent reduction in mortality from drug-resistant infections; a 20 percent reduction in inappropriate human antibiotic use; and a 30 percent reduction in inappropriate animal antibiotic use.These goals should be achievable, Cook says. Listen as she tells One World, One Health about some concrete ways the world can work together to control the spread of drug-resistant germs.Learn more about the struggle to control drug-resistant bacteria, viruses, and fungi in some of our other episodes. We've spoken with experts about how vaccines can help prevent the spread of drug-resistant germs, about tracking superbugs in sewage, and the surprising rise of drug-resistant fungi. Experts in drug design have talked to us about the search for new and better antibiotics and how these little organisms are winning an arms race against us. Filmmakers have told us about how storytelling can help people understand the threat while global health specialists explained that good stewardship can keep the antibiotics we have working as they should. We've even investigated superbug mysteries, like the case of the killer eyedrops.
In this episode, we review the high-yield topic of Drug Resistance from the Microbiology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message
Timestamps: 5:15 - Having a co-founder pass away 10:33 - Drug resistance and cancer patients 18:24 - Clinical development 23:17 - Raising a series A as a biotech 26:43 - Striking partnerships Check out the LinkedIn event for our livestream with Aurelio Perucca on May 22nd. About Stefanie Flückiger-Mangual: Stefanie Flückiger-Mangual is the co-founder and CEO at TOLREMO Therapeutics, a biotech startup on a mission to prevent non-genetic cancer drug resistance. She holds a PhD in Molecular and Translational Biomedicine from ETH and worked there as a Postdoctoral Researcher before starting TOLREMO in 2017 together with Wilhelm Krek, who has since tragically passed away. There is no shortage of cancer therapies in biotech and medtech, and one common problem that they face is drug resistance: even if a certain therapy is at first successful in reducing the tumor's size, patients sometimes develop a resistance to it, whether it be genetic or non-genetic, and the therapy stops working. To use a tech metaphor, genetic drug resistance is akin to a hardware problem, whereas non-genetic drug resistance is more similar to a software malfunction. Since non-genetic resistance is much more dynamic, it's harder to measure and combat — this is what Stefanie and her fellow researchers have been studying for the past few years. They discovered a pivotal mechanism that governs critical transcriptional resistance pathways, i.e., that stops cancer drug resistance as it emerges without interfering with cancer-unrelated pathways. TOLREMO recently completed its Series A financing, bringing their total amount raised to USD 39M. Their ultimate goal is to prove the efficacy of their treatment and join forces with a larger pharma company. Don't forget to give us a follow on Twitter, Instagram, Facebook and Linkedin, so you can always stay up to date with our latest initiatives. That way, there's no excuse for missing out on live shows, weekly giveaways or founders' dinners.
In this episode, host Alyssa Watson, DVM, talks to Ray M. Kaplan, DVM, PhD, DEVPC, DACVM (Parasitology), about his recent Clinician's Brief article, “Diagnosing Drug Resistance in Canine Hookworms via Fecal Egg Count Reduction Test.” Resistant hookworms are no longer uncommon, so Dr. Kaplan joined us to break it down. He details how to diagnose resistance by comparing pretreatment and 14-day posttreatment egg counts using a fecal egg count reduction test. Dr. Kaplan then explains how and when to use “triple therapy” in cases when resistance is confirmed.Sponsored by Merck Animal HealthResource:https://www.cliniciansbrief.com/article/hookworm-dogs-drug-resistance-diagnosishttps://www.cliniciansbrief.com/article/persistent-or-suspected-resistant-hookworm-infectionshttps://UnlockBetterProtection.comContact us:Podcast@briefmedia.comWhere to find us:Youtube.com/@clinicians_briefCliniciansbrief.com/podcastsFacebook.com/cliniciansbriefTwitter: @cliniciansbriefInstagram: @clinicians.briefThe Team:Alyssa Watson, DVM - HostAlexis Ussery - Producer & Multimedia Specialist
In this podcast, I talk about how we've developed an accurate, user friendly and cost effective whole genome sequencing tool using Oxford Nanopore Technologies' MinION device for diagnosing drug-resistant tuberculosis in resource constrained settings. All my posts have links to online resources that you might find useful, and you can find the link to this particular blog here.
It's not a worm, it's a fungus among us. Today's topic is ringworm. Joining me today is Regents Professor of Clinical Laboratory Science at Texas State University and author of an article published in The Conversation last year, but a topic still worth discussing. Ringworm fungal infections are common in the US and are becoming increasingly resistant to treatment
Drug-resistant infections are a problem for everyone, but especially for newborns. They don't have fully developed immune systems, and their bodies are less equipped to fight infections.The risk is highest for infants born sick or prematurely. Bloodborne infections – sepsis – are one major threat to newborns. Sepsis can move quickly, overpowering the body and causing severe illness and even death within hours. Doctors don't have time to test babies to see what's infecting them and have to treat them based on what Dr. Mike Sharland calls a best guess. These infections are often resistant to the drugs that are available to treat them, too. National and international guidelines can help doctors make difficult and life-altering decisions about treatment, but there's not much guidance for health professionals treating newborns. That's in part because there is so little research on which antibiotics work in newborns. Sharland, a pediatric infectious disease specialist at St George's University of London, is helping lead a group running the clinical trials needed to form the basis of guidelines.In this episode, Dr. Sharland tells us about the terrifying growth of drug-resistant infections in newborns and the need for better antibiotics for these vulnerable babies.
Brazil's Proactive Measures Against HIVBrazil has been at the forefront of combating HIV, implementing proactive measures that have made a significant difference. The country began providing no-cost access to CD4 and viral load testing and antiretroviral drugs as early as 1996. This early intervention and consistent approach led to a remarkable outcome: the number of HIV cases in Brazil was significantly lower than initially predicted. An article from the New England Journal of Medicine stated that initial estimates predicted Brazil would have 1.2 million people infected with HIV by the year 2000, but with the strategies the country put in place, their actual numbers were about half of what was predicted. By offering free access to treatments and diagnostic tests, Brazil showcased the importance of early and sustained intervention in managing and reducing the spread of HIV. The Rising Challenge of HIV Drug ResistanceOne of the most pressing challenges in the fight against HIV is the development of drug resistance. Dr. Ricardo Diaz emphasizes that as the HIV virus replicates, it can produce strains resistant to treatment. This resistance threatens the efficacy of antiretroviral drugs, making it crucial to monitor and manage. The World Health Organization reports an increasing rate of HIV drug resistance, underscoring the need for continuous research, monitoring, and adaptation of treatment strategies. Pre-exposure Prophylaxis (PrEP) Drugs Exist, but are not 100% EffectivePrEP, or pre-exposure prophylaxis, is also an antiretroviral drug given to uninfected individuals who are at risk of infection to reduce their chances of acquiring HIV. PrEP is highly effective at preventing HIV when taken as indicated, but much less effective when it isn't taken consistently. Additionally, it's possible to be exposed to HIV strains that are drug resistant while on PrEP, so monitoring resistance in people on PrEP is another important step in prevention. The Gap in HIV Drug Resistance TestingDespite the advancements in treatment, there's a noticeable disparity in HIV drug resistance testing, especially in Brazil. Dr. Diaz highlights that while a centralized lab in Brazil performs genotype testing, the number of tests conducted falls short of the actual need. With 10% of patients on treatment showing a viral load above the desired limit, the demand for resistance testing is evident. Bridging this gap and increasing surveillance efforts is essential to tailor treatments effectively and combat the spread of drug-resistant HIV strains.
Resident GP and CEO of Proactive Health Solutions, Dr Fundile Nyati on concerns against the unnecessary use of antibiotics as it may lead to resistance, as we observe World Antimicrobial Awareness Week (18 –24 November), the Gauteng Department of Health has urged the public to avoid the misuse of antibiotics. See omnystudio.com/listener for privacy information.
We are pleased to be joined by Dorothy Achu, Regional Malaria Adviser, WHO African Region; Aimable Mbituyumuremyi, Director, National Malaria Control Program, Ministry of Health, Rwanda; Adam Aspinall, Senior Director, Access and Product Management, and George Jagoe, Executive Vice-President Medicines for Malaria Venture. To learn about antimalarial drug resistance in Africa to ensure patients can continue to be saved.
Vaccines are lifesavers. Childhood vaccines save 4 million lives every year, according to the US Centers for Disease Control and Prevention. And it turns out vaccines don't just save lives by directly preventing disease. They can save lives by reducing the rise of drug-resistant pathogens (mostly bacteria and viruses). This is because people who are vaccinated are less likely to get sick and to get treated either appropriately or inappropriately with antibiotics and antiviral drugs. And less use of these valuable drugs means less opportunity for germs to develop resistance to them. The One Health Trust set out to quantify just how well vaccination could reduce the emergence and spread of antimicrobial resistance or drug-defying germs. The latest report from the One Health Trust pulls together a variety of studies showing the impact of vaccines not only on drug resistance but also on economies, especially in low- and middle-income countries. Some highlights: A typhoid vaccination campaign for infants could prevent more than 53 million cases of drug-resistant typhoid in low- and middle-income countries over 10 years. A successful rotavirus vaccination program in Africa and Asia could prevent more than 13 million cases of diarrhea that otherwise would be treated with antibiotics – reducing opportunities for bacteria to evolve resistance to those drugs. In Indonesia alone, vaccinating 50% of eligible people with pneumococcal vaccine over five years could save more than US$2 million in costs related to treatment failure. One Health Trust Fellow and Director of Partnerships, Dr. Erta Kalanxhi, led the team that put together the report. Listen as she chats with One World, One Health host Maggie Fox about how vaccines can prevent the rise of drug-resistant bacteria and viruses.
Drug resistance is one of the most serious health threats facing humanity. Bacteria, fungi, viruses, and parasites are learning more and more to resist the medicines that are meant to kill them. These 'superbugs' can spread easily, increasing the risk of prolonged illness, or even death, from common infections. And the danger for cancer patients is particularly high. One of the reasons is the overuse and misuse of antimicrobial medicines. By 2050, Antimicrobial Resistance (AMR) could cause 10 million deaths per year and cost more than USD 100 trillion to public health - if no action is taken.On the occasion of World Antimicrobial Awareness Week from 18-23 November, Cary Adams, UICC's CEO speaks with Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance and former Chief Medical Officer for England.Cary Adams, UICC's CEO speaks with Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance and former Chief Medical Officer for England. Hosted on Acast. See acast.com/privacy for more information.
Drug-defying superbugs can be found in manure, soil, the ocean, and especially in sewers. These places are sources of infection, but they also provide a way to keep an eye on which drug-resistant germs are where – and how much they are changing. The World Health Organization encourages mapping all of the places drug-resistant organisms are popping up, and what kind of organisms there are. “If no action is taken, AMR (antimicrobial resistance) could cost the world's economy US$ 100 trillion by 2050,” WHO says. Windi Muziasari, PhD, became passionate about tracking these deadly germs while doing postdoctoral research at the University of Helsinki in Finland. The Indonesian-born scientist founded her own company to do this mapping for governments, communities, and companies. As Founder and CEO of ResistoMap, Muziasari has looked for drug-resistant microbes in agricultural runoff, in hospitals, under city streets, among wildlife, and elsewhere in dozens of countries. The hope is to act as an early warning system so that companies, governments, and others can do something about the problem. “Almost everywhere is polluted,” she tells us on the One World, One Health podcast. Listen as Windi Muziasari tells host Maggie Fox about how and why she got started and what she's learned since launching ResistoMap.
In this episode, Shannon Kasperbauer, MD, discusses guideline-based treatment recommendations for people with M. abscessus, including a discussion of:Macrolide resistancePredictors for disease progression2020 NTM guideline recommended treatment optionsEmerging therapiesWe will also hear from a patient who describes how she remained adherent during long courses of treatment for M. abscessus.Finally, we hear Dr Kasperbauer discuss a patient case with her colleagues, Charles L. Daley, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MDProfessor of MedicineDivision of Mycobacterial and Respiratory Infections National Jewish HealthDenver, ColoradoShannon Kasperbauer, MDAssociate Professor of MedicineDivision of Mycobacterial and Respiratory InfectionsNational Jewish HealthDenver, ColoradoPamela J. McShane, MDProfessor of MedicineDivision of Pulmonary and Critical Care MedicineThe University of Texas Health Science Center at TylerTyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G
BUFFALO, NY- October 11, 2023 – A new research paper was published in Oncotarget's Volume 14 on October 4, 2023, entitled, “Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells.” Drug resistance is a major barrier against successful treatments of cancer patients. Gain of stemness under drug pressure is a major mechanism that renders treatments ineffective. Identifying approaches to target cancer stem cells (CSCs) is expected to improve treatment outcomes for patients. In their new study, researchers Astha Lamichhane, Gary D. Luker, Seema Agarwal, and Hossein Tavana from The University of Akron, University of Michigan and Georgetown University aimed to elucidate the role of cancer stemness in resistance of colorectal cancer cells to targeted therapies. “[...] we developed spheroid cultures of patient-derived BRAFmut and KRASmut tumor cells and studied resistance mechanisms to inhibition of MAPK pathway through phenotypic and gene and protein expression analysis.” They found that treatments enriched the expression of CSC markers CD166, ALDH1A3, CD133, and LGR5 and activated PI3K/Akt pathway in cancer cells. The team examined various combination treatments to block these activities and found that a triple combination against BRAF, EGFR, and MEK significantly reduced stemness and activities of oncogenic signaling pathways. This study demonstrates the feasibility of blocking stemness-mediated drug resistance and tumorigenic activities in colorectal cancer. “Our approach to identify mechanisms of drug resistance of patient-derived cancer cells to targeted therapies and develop effective treatments is promising toward cancer precision medicine.” DOI - https://doi.org/10.18632/oncotarget.28517 Correspondence to - Hossein Tavana - tavana@uakron.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28517 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, drug resistance, cancer stem cells, patient-derived tumor model, colorectal cancer, combination treatment About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Researchers examine the rise of artemisinin drug resistance in Eritrea - and search for its genetic basis. Transcript Artemisinin – a key antimalarial drug – and other drugs derived from it, are fast losing their effectiveness across South East Asia and increasingly in Africa, too. To investigate this, researchers conducted a review of drug efficacy studies in the East African country of Eritrea. They looked for the rates of delayed parasite clearance in the three days following treatment – a key marker of partial drug resistance. They found a troubling pattern: delayed parasite clearance climbed from 0.4% in 2016 to 1.9% in 2017, followed by a marked increase to 4.2% in 2019. By isolating and sequencing parasitic DNA, they found that this trend was associated with the rise of a novel mutation to the Kelch13 region of the parasite, called R622I. Given the lack of alternative drugs, the emergence of resistance in Africa is concerning. Source Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea About The Podcast The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.
Deputy Editor Adrian Gonzalez interviews Lawrence Mbuagbaw (McMaster University, Ontario, Canada) about the CEDRIC-HIV checklist and its value in enhancing transparency, interpretation, comparability, and replicability of HIV drug resistance studies.Read the full article:https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(23)00173-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhivContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Are you tired of the same old cancer treatment methods that leave you feeling drained and hopeless? Look no further than the Integrative Cancer Solutions with Dr. Karlfeldt. In our latest episode, we have Dr. Stephen Iacoboni, a medical oncologist with over 40 years of experience, discussing the use of naturopathic remedies alongside chemotherapy to overcome drug resistance. Our goal is to educate and inform our listeners about alternative cancer solutions that have been successful for others. Dr. Iacoboni shares his expertise in integrative oncology and explains why he believes that academic institutions have a primary mission of research, while a doctor in the community has a primary mission of patient care. The conversation also touches on the pros and cons of chemotherapy and the emerging direction of immunotherapy. Join us as we explore the history and progress of cancer treatment, breakthroughs in oncology, and alternative tools and treatments. Don't miss out on this informative and eye-opening episode. Tune in to Integrative Cancer Solutions with Dr. Karlfeldt today.- Alternative cancer treatments- Naturopathic remedies- Integrative oncology- Evolution of medical oncology- Pros and cons of chemotherapy- Immunotherapy limitations- Insulin Potentiated Therapy- Hyperoxidative therapy- Exploiting cancer cell vulnerabilities- Antioxidants and cancer- Nutraceuticals in cancer treatment- Revolution in oncology- Telos book and purpose in life- Scientific atheism and faith- Patient-centered care- Educational purposes only- Karlfeldt Center promotionKEY POINTS[0:0:32] With integrative and holistic methods, it's possible to WIN the fight against cancer.[0:5:16] Academic institutions are dedicated to pushing the boundaries of knowledge, while doctors are devoted to providing life-saving care to their patients.[0:8:53] In the last four decades, medical oncology has seen a remarkable transformation, from primitive radiation and surgical treatments to the development of revolutionary chemotherapy and immunotherapy treatments.[0:14:22] Shockingly, traditional cancer therapies often come with debilitating side effects - but luckily, there are now alternative solutions available![0:16:44] Miraculously, over 90% of early stage cancer cases can be successfully cured – giving hope to those facing the devastating diagnosis of stage four cancer.[0:21:39] By strategically targeting the oxidative state of cancer cells with Vitamin C and K3 at a specific ratio, researchers have uncovered an incredibly empowering and overlooked vulnerability in the fight against cancer.[0:22:10] Chemotherapy is a much less lethal and more effective alternative to Cyanide for treating cancer, with the power to eradicate cancerous cells on a much larger scale.[0:26:25] Cancer cells exhibit an alarming, frenetic energy level, devouring vast amounts of energy to fuel their rapid growth.[0:27:42] By leveraging the power of Prooxidants, cancer cells can be efficiently destroyed with reduced chemo doses, effectively cutting off their crucial supply of antioxidants![0:30:20] Despite the exorbitant price of cancer medications, some physicians prioritize patient health above profit, delivering effective and accessible treatments to improve the lives of those affected.[0:36:22] By revolutionizing oncology, we could dramatically reduce Medicare costs, saving billions of dollars and dramatically improving the lives of countless patients.[0:46:24] Incredibly, nutraceuticals with hyperoxidation properties have the potential to halt the progression of pre-cancerous cells, offering a cost-effective alternative to traditional cancer prevention methods. Connect with Stephen at https://stepheniacoboni.com/ Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. For more information about products and services discussed in this podcast, please visit www.integrativecancersolutions.com. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com.
Cancer ki Baat - Dr. Minish Jain ke saath (कैंसर की बात, डॉ. मिनिष जैन के सा
Resistance can occur when cancer cells—even a small group of cells within a tumor—contain molecular changes that make them insensitive to a particular drug before treatment even begins. Because cancer cells within the same tumor often have a variety of molecular changes, this so-called intrinsic resistance is common. Lets learn more about this in this episode. See you soon. Jai Hind
In this episode, Christine Katlama, MD, and Babafemi Taiwo, MBBS, discuss optimizing ART for people with HIV who are treatment experienced or failing a current ART regimen, including:Recycling agents from the NRTI, NNRTI, INSTI, and PI classes in salvage ART regimensMaintaining NRTIs in second-line and salvage ART regimens, including the use of 3TC, TFV, and ABCART regimen simplificationWhen to perform genotypic resistance testing, including for PWH who have been off ARTWhen to perform DNA genotyping for archived resistance testingConsidering LA CAB + RPV with prior NNRTI exposure, ART resistance, or past adherence concerns with oral ARTUsing boosted DRV + DTG in salvage regimensSwitching from boosted PIs to INSTIs in PWH receiving second-line therapySecond-line regimens with LA CAB + RPV failure Christine Katlama, MD Professor Sorbonne University APHP Paris Head, HIV/Hepatitis Clinical and Research Unit Department of Infectious Diseases Paris, France Babafemi Taiwo, MBBS Gene Stollerman Professor of Medicine Chief, Division of Infectious Diseases Northwestern University Feinberg School of Medicine Chicago, Illinois Link to full program: https://bit.ly/3Z44Gq3
Consumption. The White Plague. Scrofula. Tuberculosis (TB) has been known by so many names over the ages, and those names reflect just how long it's been around and just how misunderstood it's been. It's killed kings and generals, playwrights, and poets.TB still sickens 10 million people every year and kills 1.5 million – even though it's easily prevented and can be treated. It's unusual because it needs to be treated even if the person infected has no symptoms at all.And even though it's an ancient disease, TB keeps evolving into new and ever more unpleasant forms. Now, multi-drug-resistant (MDR) TB infects half a million people around the world each year, according to the World Health Organization. A third of these MDR TB infections go undetected, and that means there are tens of millions of people who do not get the treatment they need and who can go on to infect others.Dr. Jeffrey Tornheim has been studying ways to test people to quickly and easily tell if they've got a drug-resistant form of TB infection and need special medications to treat it right away. Quick information can help stop the spread of these dangerous forms of the infection and can ensure that patients and health professionals don't waste time, money, and medicine with the wrong treatments. In this episode of One World One Health, Dr. Tornheim, Assistant Professor of Medicine and Assistant Professor of Pediatrics at the Johns Hopkins University School of Medicine, as well as at the Johns Hopkins Bloomberg School of Public Health, chats with host Maggie Fox about why TB is so hard to fight and how genomics can make that fight a little easier.
Not every behavior change intervention goes to plan, and in this podcast we talk about what happens when poorly thought out social-science or behavior change interventions are launched into the wild. It's one thing to have no measurable effect, but it's entirely another to have the opposite of your intended effect on behavior at large. Join us as we talk D.A.R.E., incentivizing people to get vaccinated, and other "backfires" in behavior change.If you have any questions, feedback, or just want to say hi, email us at medicalanthropology@havas.comCheck out Brad and Sonika's LinkedIn profiles to get notified when a new episode is out:https://www.linkedin.com/in/brad-davidson-3815222https://www.linkedin.com/in/sonikagarcia
In this episode, José R. Arribas, MD, and Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP, discuss optimizing antiretroviral therapy (ART) for people with HIV who are treatment experienced or failing a current ART regimen, including:The use of proviral DNA genotyping for switching therapyMaintaining nucleos(t)ide reverse-transcriptase inhibitors after a first failureThe role of zidovudine in salvage regimensThe use of twice-daily darunavir with protease inhibitor resistance and twice-daily dolutegravir with integrase strand transfer inhibitor resistanceSimplification of regimens and long-acting therapies for people with HIV who are highly treatment experiencedDrug‒drug interactions that may warrant dosing changes to avoid resistance developmentWhen to consider antiretrovirals with novel mechanisms of action, such as fostemsavir, ibalizumab, and lenacapavirThe logistics of dosing, administration, and development of a complete ART regimen that includes novel mechanism antiretroviralsAddressing psychosocial factors to increase the chance of success on a new ART regimenDrug‒drug interactions with novel mechanism agentsHow common ART resistance is for people with HIV in their own practicesThe possibility of using long-acting cabotegravir plus rilpivirine in people with viremia in the futureAddressing low-level viremiaJosé R. Arribas, MDProfessor of MedicineDepartment of MedicineAutónoma University School of MedicineHead, Infectious Diseases UnitDepartment of Internal MedicineHospital La PazMadrid, SpainMelissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVPClinical Associate ProfessorSection of Infectious Diseases Pharmacotherapy Department of Pharmacy PracticeUniversity of Illinois at Chicago, College of PharmacyChicago, IllinoisLink to full program:bit.ly/3Z44Gq3
Madeleine Finlay speaks to Guardian science correspondent Linda Geddes about the possibility of a fungal pandemic like the one depicted in apocalyptic thriller The Last of Us. They discuss the strange world of fungi, the risks of infections and treatment resistance, and what we can do to protect ourselves from future fungal threats. Help support our independent journalism at theguardian.com/sciencepod
Just about everyone has had an unpleasant fungal encounter, usually something as simple as athlete's foot, ringworm, or dandruff.But fungal infections can become much more dangerous and even deadly, especially in people whose immune systems are damaged by another infection such as HIV, tuberculosis, or even COVID-19. Mold species such as aspergillus are in the air all the time and when breathed in by someone whose immune system is damaged, they can cause an infection known as aspergillosis. Another infection, candida auris, spreads in hospitals and can kill. More than 300 million people have such infections and 1.5 million die from them, according to recent estimates.In this episode, Dr. David Denning, a retired professor of infectious diseases, global health, and medical mycology at Wythenshawe Hospital and the University of Manchester, chats with One World, One Health host Maggie Fox about the threat of fungal diseases, especially as people alter their environments.Denning is the founding president, executive director, and chief executive of Global Action For Fungal Infections (GAFFI), which focuses on the global impact of fungal disease.Listen as Dr. Denning describes the need for new, resistance-busting medications to fight fungal infections, better testing to diagnose them, and better awareness of the threat.
The malaria parasite is becoming increasingly resistant to the drugs we use against it. Caroline Simmons, a geneticist at the University of South Florida, is trying to understand what's driving this. By creating mutants of the parasite, and testing drugs against them, she's piecing together the complex puzzle of antimalarial drug resistance.
We're back for season 3! In the season opener, Dr. Philip Chan from the Rhode Island Department of Health talks about the rising number of sexually transmitted infections in Rhode Island and nationwide. He's joined by Kathleen Roosevelt, the director of STD prevention and HIV surveillance at the Massachusetts Department of Public Health, and Dr. Kathy Hsu, the medical director for that division at MDPH. The three experts focus their discussion on gonorrhea: what is it? How is it treated? How does it spread? They also talk about two recent cases in Massachusetts that are getting nationwide attention after showing evidence of reduced susceptibility to antibiotics. Download the season 3 premiere to learn more about gonorrhea and local resources for STI prevention, testing, and treatment in Rhode Island.
Facts & Spin for February 8, 2023 top stories: US Fed chairman Powell says the inflation fight may last a while, Fighting intensifies in Eastern Ukraine, A UN report finds unemployment is driving militants in sub-Saharan Africa, A court rules South Korea must compensate a Vietnam War victim, A Kenya Judge says that Meta can be sued by an ex-moderator, Migrants in New York City are given one-way tickets to Canada, A report concludes NYPD officers should be punished for their 2020 BLM protest response, Polls show Low enthusiasm for a Biden re-run, Antibiotic Use in Farming is projected to Climb Amid Fears of Drug-Resistance, and More Than a Third of US Plants and Animals are believed to be at Risk of Extinction. Sources: https://www.improvethenews.org/ Brief Listener Survey: https://www.improvethenews.org/pod
Dr. Kelly Diehl discusses MRSA and pets with Dr. Meghan Davis of Johns Hopkins University. The pair talk about Dr. Davis's research on how MRSA, people and pets intersect, and they discuss steps pet parents can take to keep their pets – and themselves – safe.
In this episode, Marion Elligsen, BScPhm, MSc, RPh, ACPR; Keith S Kaye, MD, MPH; and Andrew Shorr, MD, MPH, MBA, discuss key considerations for selecting empiric antibiotic regimens in patients with HABP/VABP in the intensive care unit, including: The role of novel β-lactam/β-lactamase inhibitor combinationsUse of clinical predictions scores (eg, Drug Resistance in Pneumonia [DRIP] score) to predict risk for pneumonia caused by multidrug-resistant pathogensApplication of rapid diagnostic testing in critically ill patients with pneumonia, including current limitationsImplementation of advanced antibiograms and clinical prediction scoresClinical utility of biomarkers for pneumonia (eg, procalcitonin)Application of updated nosocomial pneumonia classifications in clinical practiceFaculty:Marion Elligsen, BScPhm, MSc, RPh, ACPRPractice-Based ResearcherSunnybrook Research InstituteAntimicrobial Stewardship Pharmacy LeadDepartment of PharmacySunnybrook Health Sciences CentreToronto, Ontario, CanadaKeith S. Kaye, MD, MPHChief Division of Allergy, Immunology and Infectious DiseasesProfessor of MedicineRutgers Robert Wood Johnson Medical SchoolNew Brunswick, New JerseyAndrew Shorr, MD, MPH, MBADirectorPulmonary and Critical Care MedicineMedstar Washington Hospital CenterWashington, DCContent based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp. Link to full program:https://bit.ly/3HaZpYwLink to downloadable slideset:https://bit.ly/3UxHoqr
In this episode, Dr. Nicholas White of the University of Oxford in the UK and Mahidol University in Thailand tells us how the world is losing ground in the fight against malaria, in no small part because of the emergence of resistance.Malaria is caused by a parasite transmitted by mosquitoes, and these parasites have repeatedly evolved to escape the effects of drug after drug over the decades. Now, Dr. White argues, there's a chance to get out ahead of this resistance. How?Listen as he tells our host Maggie Fox how the parasite manages to evade the effects of drugs and what he thinks needs to be done to stop it from happening yet again.
Ahmet Acar, Team Leader/Assistant Professor, CEO & Founder HistoCan Precision Medicine and Drug Resistance Lab, Department of Biological Sciences, Middle East Technical University, Ankara, TURKEY speaks on "Developing quantitative experimental model systems to study drug resistance".
Dr. Nagourney discusses the development of drug resistance in colon cancer patients that contributed to the failure of the oxaliplatin-based HIPEC PRODIGE 7 Trial
Editor-in-Chief, Peter Hayward, talks to researchers from London School of Hygiene and Tropical Medicine and Melanie Alufandika-Moyo Malawi-Liverpool Wellcome Trust about their research on virological failure and HIV drug resistance in patients with HIV in hospital in Malawi.
Dr. John Conly,member of the expert panel that authored the Council of Canadian Academies report talks about drug resistance likely to kill 400000 Canadians by 2050
Antibiotics are a pillar of modern medicine. They have saved millions of lives. But as the use of antibiotics has increased, so has the proliferation of antibiotic-resistant microbes that have adapted to survive most, or all, of today's antibiotics. The CDC reports that two million people are infected with drug-resistant bacteria every year in the United States, and the Review on Antimicrobial Resistance estimated that, around the world, 700,000 people die of such infections annually. That number stands to increase: the Review predicts that, by 2050, drug resistance could be responsible for 10 million deaths a year. And while these numbers are dominated by bacterial infections, fungal infections like Candida auris are also a threat, especially to vulnerable patients in hospitals and nursing homes. Despite drug resistance growing, the development of new antibiotics has slowed. How can policymakers help accelerate the pace of new drug development, and how can all of us—doctors, hospitals, and patients, as well as the agricultural sector—be better stewards of existing drugs? Forum panelists examined the scope of this looming crisis and look at how changes in policy and practice can help us stay one step ahead of these superbugs. Watch the entire series: https://theforum.sph.harvard.edu/
According to the World Malaria Report, there were 219 million cases of malaria globally during 2017, resulting in 435,000 malaria deaths. Drug resistance poses one of the greatest threats to malaria control and results in increased malaria morbidity and mortality. Vanderbilt University biomedical engineers have discovered how to rapidly detect critical information about malaria drug resistance almost instantly from a patient's single drop of blood. Joining me today to discuss this quick DNA test is Mindy Leelawong. PhD. Dr Leelawong is a research assistant professor of biomedical engineering at Vanderbilt University.
© 2020-2025 Ivy Podcast Discovery LLC
